Insights from 2023 SABCS


 

SABCS 2023 Insights: "PROs From the CAPItello-291 Trial Investigating Capivasertib and Fulvestrant for Patients With Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"

606 views
December 15, 2023
Comments 0
Login to view comments. Click here to Login